Cargando…

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Yoshiko, Sakurada, Yoichi, Matsubara, Mio, Hasebe, Yuka, Sugiyama, Atsushi, Kikushima, Wataru, Kashiwagi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469297/
https://www.ncbi.nlm.nih.gov/pubmed/34572350
http://dx.doi.org/10.3390/biomedicines9091164
_version_ 1784573894846316544
author Fukuda, Yoshiko
Sakurada, Yoichi
Matsubara, Mio
Hasebe, Yuka
Sugiyama, Atsushi
Kikushima, Wataru
Kashiwagi, Kenji
author_facet Fukuda, Yoshiko
Sakurada, Yoichi
Matsubara, Mio
Hasebe, Yuka
Sugiyama, Atsushi
Kikushima, Wataru
Kashiwagi, Kenji
author_sort Fukuda, Yoshiko
collection PubMed
description We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (p = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (p = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA.
format Online
Article
Text
id pubmed-8469297
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84692972021-09-27 Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy Fukuda, Yoshiko Sakurada, Yoichi Matsubara, Mio Hasebe, Yuka Sugiyama, Atsushi Kikushima, Wataru Kashiwagi, Kenji Biomedicines Article We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (p = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (p = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA. MDPI 2021-09-05 /pmc/articles/PMC8469297/ /pubmed/34572350 http://dx.doi.org/10.3390/biomedicines9091164 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fukuda, Yoshiko
Sakurada, Yoichi
Matsubara, Mio
Hasebe, Yuka
Sugiyama, Atsushi
Kikushima, Wataru
Kashiwagi, Kenji
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
title Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
title_full Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
title_fullStr Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
title_full_unstemmed Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
title_short Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
title_sort comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469297/
https://www.ncbi.nlm.nih.gov/pubmed/34572350
http://dx.doi.org/10.3390/biomedicines9091164
work_keys_str_mv AT fukudayoshiko comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy
AT sakuradayoichi comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy
AT matsubaramio comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy
AT hasebeyuka comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy
AT sugiyamaatsushi comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy
AT kikushimawataru comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy
AT kashiwagikenji comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy